ArticleClinical rheumatology2022

The effectiveness of tocilizumab in treating refractory adult-onset Still's disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response.

Kuo-Tung Tang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.